Review Article

Volume – 1, Issue-1, 2025
Journal home Page: https://farpublisher.com/farjams/
Page: 08-13
Publication Month: Feb.2025

OPEN ACCESS

Intersecting Pathologies: HIV and Sickle Cell Anemia in Clinical Management

By

Emmanuel Ifeanyi Obeagu[1] and Priya Homa Chukwu[2]

[1]Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, [2]Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science, Rivers State University of Science and Technology, Port Harcourt, Rivers State.

Abstract

The intersection of HIV and Sickle Cell Anemia (SCA) presents a unique and complex clinical challenge, as both conditions independently contribute to chronic inflammation, immune dysfunction, and vascular complications. HIV infection exacerbates hemolysis, anemia, and vaso-occlusive crises (VOCs) in SCA patients, increasing morbidity and mortality. The dual burden of these diseases is particularly significant in sub-Saharan Africa, where both conditions have high prevalence rates. Understanding the intricate pathophysiological interactions between HIV and SCA is crucial for improving patient outcomes and developing targeted therapeutic strategies. Managing HIV-positive SCA patients requires a multidisciplinary approach due to overlapping complications and potential drug interactions. Antiretroviral therapy (ART) can influence hematologic parameters, with some regimens exacerbating anemia and others requiring careful selection to minimize toxicity. Additionally, SCA-related complications such as stroke, acute chest syndrome, and infections are more severe in the presence of HIV-induced immune suppression. Blood transfusions, hydroxyurea therapy, and supportive care must be carefully tailored to balance the risks and benefits in this vulnerable population.

Keywords: *HIV, Sickle Cell Anemia, Vaso-Occlusion, Immunopathology, Antiretroviral Therapy*

Introduction

HIV and Sickle Cell Anemia (SCA) are two chronic conditions that independently pose significant health burdens, particularly in sub-Saharan Africa, where their prevalence is highest. HIV is a viral infection that progressively weakens the immune system, leading to increased susceptibility to opportunistic infections and chronic inflammation. SCA, on the other hand, is a genetic blood disorder characterized by the production of abnormal hemoglobin S, leading to hemolysis, anemia, and recurrent vaso-occlusive crises (VOCs). When these two conditions coexist in a patient, they create a complex clinical landscape requiring specialized management strategies to address overlapping complications.[1-2] The intersection of HIV and SCA presents unique challenges due to their shared impact on the immune system and vascular health. SCA patients already experience chronic inflammation, endothelial dysfunction, and heightened susceptibility to infections, which are further exacerbated by HIV-induced immunosuppression. Additionally, both diseases contribute to oxidative stress and organ damage, increasing the risk of multi-system complications such as kidney disease, stroke, and acute chest syndrome. Understanding how these conditions interact at the molecular and clinical levels is essential for optimizing treatment approaches and improving patient outcomes.[3-4] One of the key concerns in managing HIV-positive SCA patients is the effect of HIV on hematologic parameters. HIV infection can worsen anemia through bone marrow suppression, nutritional deficiencies, and ART-related toxicities. SCA patients, who already experience chronic hemolysis, may suffer more severe anemia when co-infected with HIV, complicating treatment strategies. Moreover, HIV-associated thrombocytopenia and altered coagulation pathways may further exacerbate the vaso-occlusive events commonly observed in SCA, leading to increased hospitalization and mortality rates.[5-6]

Another major challenge is the management of ART in individuals with SCA. While ART is essential in suppressing viral replication and preserving immune function, certain antiretroviral drugs, such as zidovudine, are known to induce bone marrow suppression and exacerbate anemia. This necessitates careful selection of ART regimens to minimize hematologic complications while ensuring effective viral control. Additionally, hydroxyurea, the primary disease-modifying therapy for SCA, may have potential interactions with ART, which remain largely unexplored in clinical research.[7-8] Beyond hematologic concerns, HIV-SCA co-infected individuals face a heightened risk of infections, including pneumonia, osteomyelitis, and bloodstream infections, due to the combined effects of immune dysregulation and splenic dysfunction. Preventive strategies such as vaccination, prophylactic antibiotics, and close monitoring for infections are crucial in reducing morbidity. Furthermore, the management of SCA-related complications, such as VOCs and stroke, must be adapted in the presence of HIV to avoid excessive immunosuppressive therapies that could further weaken host defenses.[9-10] Despite the increasing recognition of HIV-SCA co-infection, there remains a significant gap in research regarding the long-term effects of ART on SCA progression and the best treatment approaches for these patients. Emerging therapies, including gene editing techniques such as CRISPR for SCA and novel biologics targeting inflammatory pathways, offer promising avenues

for future research. Additionally, the role of immune modulation in mitigating disease severity in co-infected individuals needs further exploration to enhance therapeutic interventions.[11-12]

Pathophysiological Interactions Between HIV and Sickle Cell Anemia

HIV and Sickle Cell Anemia (SCA) share overlapping pathological mechanisms that contribute to a heightened inflammatory state, immune dysregulation, endothelial dysfunction, and increased risk of vascular complications. While SCA is characterized by chronic hemolysis, vaso-occlusive crises (VOCs), and oxidative stress, HIV infection exacerbates these conditions by impairing immune responses and inducing systemic inflammation. The co-existence of these diseases leads to a complex clinical presentation that requires specialized management strategies.[13-14]

1. Chronic Inflammation and Immune Dysregulation

Both HIV and SCA contribute to chronic immune activation, albeit through different mechanisms. In SCA, the release of free hemoglobin from lysed red blood cells promotes oxidative stress and endothelial damage, triggering a persistent inflammatory response. Pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are upregulated, leading to endothelial activation and increased adhesion of sickled erythrocytes to blood vessels. In HIV, chronic immune activation results from persistent viral replication, gut microbial translocation, and opportunistic infections. The cumulative effect of these processes results in immune exhaustion, reduced T-cell function, and increased susceptibility to secondary infections in co-infected individuals.[15-16]

2. Hemolysis, Anemia, and Erythropoietic Stress

HIV-induced bone marrow suppression compounds the anemia already present in SCA due to chronic hemolysis. The virus directly affects hematopoiesis by infecting progenitor cells, leading to ineffective erythropoiesis. Furthermore, ART drugs such as zidovudine and tenofovir may exacerbate anemia by inhibiting red blood cell production. SCA patients with HIV often present with more severe anemia, necessitating frequent blood transfusions. However, repeated transfusions increase the risk of iron overload, alloimmunization, and transfusion-transmissible infections, further complicating clinical management.[17-18]

3. Vaso-Occlusive Crises and Endothelial Dysfunction

Endothelial dysfunction is a central feature of both SCA and HIV, contributing to an increased risk of vaso-occlusion, thrombosis, and ischemic complications. In SCA, sickled erythrocytes, leukocytes, and platelets adhere to the endothelium, triggering microvascular occlusion and painful crises. HIV infection exacerbates this process by inducing endothelial activation through viral proteins such as gp120 and Tat, which enhance vascular inflammation and promote pro-thrombotic states. Additionally, HIV-related coagulopathy, characterized by increased levels of tissue factor and fibrin deposition, may worsen VOC frequency and severity in SCA patients.[19-20]

4. Susceptibility to Infections

SCA patients are functionally asplenic due to repeated splenic infarctions, making them highly susceptible to encapsulated bacterial infections such as *Streptococcus pneumoniae* and *Haemophilus influenzae*. HIV further increases this susceptibility by depleting CD4+ T cells and impairing humoral immunity. This dual immunosuppression places co-infected individuals at higher risk of severe bacterial sepsis, pneumonia, and osteomyelitis. Preventive strategies, including prophylactic antibiotics, pneumococcal vaccination, and early ART initiation, are essential to reduce morbidity and mortality in this vulnerable population.[21-22]

5. Coagulation Abnormalities and Stroke Risk

SCA and HIV are both associated with hypercoagulability and increased thrombotic risk. In SCA, chronic hemolysis releases free hemoglobin, which scavenges nitric oxide (NO), leading to endothelial dysfunction and platelet activation. HIV infection further exacerbates this hypercoagulable state by inducing an imbalance in coagulation factors, increasing fibrin deposition, and promoting vascular inflammation. These factors contribute to an increased risk of stroke, deep vein thrombosis, and pulmonary embolism in HIV-positive SCA patients, necessitating close monitoring and anticoagulation therapy when indicated.[23-34]

Clinical Complications and Management Challenges

The coexistence of HIV and Sickle Cell Anemia (SCA) presents significant clinical complications that require careful management to minimize morbidity and mortality. The overlapping pathological effects of both conditions contribute to severe anemia, increased frequency of vaso-occlusive crises (VOCs), heightened infection risk, and organ dysfunction. Additionally, the interactions between antiretroviral therapy (ART) and SCA treatment complicate disease management, necessitating a multidisciplinary approach to optimize patient outcomes.[25-26]

1. Severe Anemia and Blood Transfusion Challenges

Anemia is a hallmark of both HIV and SCA, with multifactorial causes including chronic hemolysis, bone marrow suppression, nutritional deficiencies, and ART-related toxicity. HIV-associated anemia results from direct viral effects on hematopoiesis, cytokine-mediated suppression, and opportunistic infections like parvovirus B19, which can trigger aplastic crises in SCA patients. Blood transfusions are often required to manage severe anemia, but frequent transfusions pose risks of iron overload, alloimmunization, and transfusion-transmitted infections. Chelation therapy for iron overload must be carefully monitored, especially in patients receiving ART, to prevent drug interactions and toxicity.[27-28]

2. Increased Frequency and Severity of Vaso-Occlusive Crises

VOCs, a hallmark of SCA, become more frequent and severe in HIV-positive patients due to increased inflammation, endothelial dysfunction, and hypercoagulability. HIV-induced immune activation further exacerbates vascular occlusion by promoting leukocyte adhesion, platelet activation, and endothelial damage. The management of VOCs requires aggressive pain control, hydration, and oxygen therapy, but opioid use must be carefully monitored to prevent dependence and adverse drug interactions with ART. Hydroxyurea, a key therapy for

SCA, may also interact with ART, potentially affecting treatment efficacy and safety.[29-30]

3. Heightened Susceptibility to Infections

SCA patients are functionally immunocompromised due to asplenia, while HIV further weakens immune defenses by depleting CD4+ T cells. This dual immunosuppression places co-infected individuals at high risk for bacterial sepsis, pneumonia, osteomyelitis, and tuberculosis. Prophylactic antibiotics, routine vaccinations (e.g., pneumococcal, meningococcal, and influenza vaccines), and early ART initiation are critical in reducing infection-related morbidity. However, immune reconstitution inflammatory syndrome (IRIS) can complicate ART initiation, leading to exaggerated inflammatory responses and worsening of pre-existing infections.[31-32]

4. Stroke and Thrombotic Complications

SCA is associated with a high risk of stroke due to chronic hemolysis, endothelial dysfunction, and hypercoagulability. HIV further increases this risk by promoting vascular inflammation and altering coagulation pathways. Silent cerebral infarcts, a common complication in SCA, may be exacerbated by HIV-related neuroinflammation, leading to cognitive impairment and poor neurodevelopmental outcomes in pediatric patients. Regular transcranial Doppler (TCD) screening, anticoagulation therapy when indicated, and early intervention with blood transfusion therapy are essential in preventing stroke in this high-risk population.[33-34]

5. ART-Related Complications and Drug Interactions

Selecting the appropriate ART regimen for SCA patients is a significant challenge due to potential drug interactions and hematologic toxicity. Zidovudine (AZT), for example, is known to cause bone marrow suppression, exacerbating anemia in SCA patients. Tenofovir can contribute to kidney dysfunction, which is already a concern in both SCA and HIV. Dolutegravir-based regimens are often preferred due to their favorable safety profile, but careful monitoring is still required. Additionally, hydroxyurea, the mainstay therapy for SCA, may have unrecognized interactions with ART, necessitating further research into its combined use with HIV medications.[35-36]

6. Multisystem Organ Damage and Chronic Complications

Both HIV and SCA contribute to progressive organ damage, affecting the kidneys, liver, lungs, and heart. Chronic kidney disease (CKD) is a major concern due to sickle cell nephropathy and HIV-associated nephropathy (HIVAN). Pulmonary complications, such as acute chest syndrome and pulmonary hypertension, are worsened by HIV-induced endothelial dysfunction and chronic inflammation. Liver dysfunction from repeated blood transfusions (iron overload) and ART-related hepatotoxicity further complicates management. Regular monitoring of organ function and early intervention strategies, including nephroprotective and cardioprotective therapies, are critical in preventing long-term complications.[37]

Current and Emerging Therapeutic Strategies

The management of HIV and Sickle Cell Anemia (SCA) co-infection presents a complex challenge requiring an integrated therapeutic approach. While current treatments primarily focus on symptom management and disease modification, emerging therapies offer promising avenues for improving patient outcomes. The interplay between antiretroviral therapy (ART), disease-modifying agents for SCA, and novel immunological and genetic therapies necessitates a multidisciplinary strategy to optimize care while minimizing adverse effects.[38]

1. Antiretroviral Therapy (ART) Optimization

Effective ART is the cornerstone of HIV management in patients with SCA. The choice of ART regimen must balance viral suppression with hematologic safety to avoid exacerbating SCA-related complications such as anemia and bone marrow suppression. Integrase strand transfer inhibitors (INSTIs), such as dolutegravir, are preferred due to their minimal hematologic toxicity. However, nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine and tenofovir should be used cautiously due to their potential to worsen anemia and kidney dysfunction, respectively. Continuous monitoring of hematologic parameters and renal function is crucial to optimizing ART regimens in this population.[39]

2. Hydroxyurea Therapy and Its Role in HIV-SCA Co-infection

Hydroxyurea is the most effective disease-modifying therapy for SCA, reducing the frequency of vaso-occlusive crises (VOCs), hospitalizations, and transfusion requirements by inducing fetal hemoglobin (HbF) production. In HIV-SCA co-infected patients, hydroxyurea may provide additional benefits by modulating inflammatory responses and improving endothelial function. However, its potential immunosuppressive effects raise concerns about increased susceptibility to infections in HIV-positive individuals. Studies are needed to determine optimal dosing strategies and long-term safety in co-infected patients.[40]

3. Blood Transfusion Therapy and Iron Chelation

Blood transfusions play a critical role in managing severe anemia and preventing stroke in SCA patients. However, repeated transfusions can lead to iron overload, increasing the risk of liver and cardiac dysfunction. Iron chelation therapy with agents such as deferasirox and deferoxamine is essential to prevent iron toxicity. In HIV-SCA co-infected patients, chelation therapy should be carefully monitored for potential interactions with ART drugs, as some iron chelators may affect ART metabolism and efficacy.[41-42]

4. Targeted Therapies for Vaso-Occlusion and Endothelial Dysfunction

Emerging therapies targeting vaso-occlusive crises and endothelial dysfunction hold promise for improving outcomes in HIV-SCA patients. Crizanlizumab, a monoclonal antibody against P-selectin, reduces VOC frequency by preventing sickled red blood cells and leukocytes from adhering to the vascular endothelium. Voxelotor, a hemoglobin polymerization inhibitor, increases oxygen affinity and reduces hemolysis, thereby mitigating anemia and vascular complications. While these drugs have shown efficacy in SCA, their effects in HIV-SCA co-infected patients remain underexplored. Future studies should assess their safety and potential interactions with ART.[43-44]

5. Gene Therapy and Curative Approaches

Gene therapy is emerging as a potential curative treatment for SCA, with CRISPR-based and lentiviral vector approaches showing promising results in clinical trials. These therapies aim to either correct the sickle mutation in the β-globin gene or reactivate fetal hemoglobin expression to counteract sickling. While gene therapy could revolutionize SCA treatment, its feasibility in HIV-SCA patients requires further investigation, particularly regarding potential immune responses and interactions with ART. Additionally, hematopoietic stem cell transplantation (HSCT) remains a curative option for SCA, but donor availability and the risk of graft-versus-host disease (GVHD) limit its widespread use.[45-46]

6. Immunomodulatory Strategies and Infection Prevention

Given the dual immunosuppressive effects of HIV and SCA, immunomodulatory therapies are being explored to enhance immune resilience and reduce inflammation. Strategies such as IL-1 and IL-6 inhibition may help mitigate chronic inflammation in co-infected patients. Additionally, infection prevention remains a cornerstone of management, with routine vaccinations (pneumococcal, meningococcal, and influenza) and prophylactic antibiotics playing a crucial role in reducing morbidity. Research into novel adjuvants and immune-boosting therapies could further strengthen host defenses in HIV-SCA individuals.[47-48]

Conclusion

The intersection of HIV and Sickle Cell Anemia (SCA) presents unique challenges in clinical management due to overlapping pathophysiological mechanisms, compounded immunosuppression, and treatment complexities. The coexistence of these conditions exacerbates anemia, increases the frequency of vaso-occlusive crises (VOCs), heightens infection susceptibility, and contributes to multisystem organ damage, necessitating a comprehensive and individualized therapeutic approach. The intricate balance between antiretroviral therapy (ART) and SCA treatments, such as hydroxyurea and blood transfusions, requires careful monitoring to minimize adverse interactions and optimize patient outcomes.

References

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. Clinical Infectious Diseases. 2015; 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. Transfusion Medicine Reviews. 2019; 33(3):162-169.
3. Ola B, Olushola O, Ebenso B, Berghs M. Sickle Cell Disease and Its Psychosocial Burdens in Africa. InSickle Cell Disease in Sub-Saharan Africa 2024: 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. The scientific world journal. 2013; 2013(1):193252.
5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Frontiers in Pediatrics. 2020; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology, 2024; 2(1): 14-33
7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024; 10(1):25-36.
10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Asian J Dental Health Sci, 2024; 4(1):32-7. Available from: http://ajdhs.com/index.php/journal/article/view/62
11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
13. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73 1
14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20- 35
15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIVExposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport International Journal of Biological and Applied Sciences (NIJBAS) 2023. http://hdl.handle.net/20.500.12493/14626
17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation. 2023; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on

atherosclerotic cardiovascular disease. Circulation research. 2024; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, Hileman CO, Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences. 2024; 25(13):7266..
20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases. 2020; 20(1):638.
23. Bhowmik A, Banerjee P. Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak. 2015; 25(2):119-123.
24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic abnormalities associated with simian immunodeficieny virus (SIV) infection mimic those in HIV infection. Journal of Medical Primatology. 2012; 41(3):214-224.
25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. Sexually transmitted infections. 2012; 88(7):528-533.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024; 2(1):33-45.
27. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
30. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
31. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies . Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
32. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
33. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
34. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
36. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy. 2015; 12:1-8.
38. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC hematology. 2014; 14:1-7.
39. Gudina A, Wordofa M, Urgessa F. Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. Plos one. 2024; 19(10):e0310239.
40. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine. 2017:99-105.
41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233.
42. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024; 2(4):68-85.
43. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral

Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi MC. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020; 15(11):e0242068.
45. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554.
46. Obeagu EI, Goryacheva OG. The Role of Inflammation in HIV and Sickle Cell Disease Co-Morbidity. Lifeline HIV, 2025; 3(1): 1-12
47. Obeagu EI, Goryacheva OG. Oxidative Stress in HIV and Sickle Cell Disease: A Double Burden. Lifeline HIV, 2025; 3(1): 13-24
48. Obeagu EI, Goryacheva OG. HIV and Sickle Cell Disease: A Focus on Liver Dysfunction. Lifeline HIV, 2025; 3(1): 25-40

